Dr. Sef P. Kurstjens, M.D., Ph.D. is an Independent Director of the Company. From April 2013 to April 2018, Dr. Kurstjens served as Chief Medical Officer at Astellas Pharma Inc. At Astellas, Dr. Kurstjens was responsible for development, regulatory affairs, medical affairs, pharmacovigilance and quality assurance and was a member of the Corporate Executive Committee. From 2010 to 2013, Dr. Kurstjens was the President and Chief Executive Officer at Agensys, Inc., an early stage oncology Astellas affiliate. From 2007 to 2010, Dr. Kurstjens served as the Senior Vice President, Chief Medical Officer and Head, Global Drug Development at Allergan plc. Dr. Kurstjens entered the pharmaceutical industry with Sandoz Pharmaceuticals (now a Novartis International AG company) in Basel, Switzerland in 1991, and from 1993 to 2005 held positions of increasing responsibility with Pfizer Inc. in both Europe and the United States, including Vice President Worldwide Therapeutic Area Head of Gastrointestinal and Genitourinary. Dr. Kurstjens received his qualifications in medicine and physiology from University of the Witwatersrand in Johannesburg, South Africa. Our board of directors believes that Dr. Kurstjens’s experience in various research and development roles for biopharmaceutical companies qualifies him to serve as a member of our board of directors.
Sef's mailing address filed with the SEC is C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVE., SUITE 100, IRVINE, CA, 92617.
Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... et Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.
Urovant Sciences Ltd executives and other stock owners filed with the SEC include: